HRC Fundamental Analysis - Hill Rom Holdings

Fundamental Rating

Taking everything into account, HRC scores 2 out of 10 in our fundamental rating. HRC was compared to 184 industry peers in the Health Care Equipment & Supplies industry. HRC may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, HRC is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year HRC was profitable.

1.2 Ratios

		Industry Rank	Sector Rank
ROA	4.97%
ROE	13.22%
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

		Industry Rank	Sector Rank
OM	17.4%
PM (TTM)	8.23%
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, HRC has less shares outstanding

The debt/assets ratio for HRC is higher compared to a year ago.

2.2 Solvency

HRC has an Altman-Z score of 3.60. This indicates that HRC is financially healthy and has little risk of bankruptcy at the moment.

A Debt/Equity ratio of 0.97 indicates that HRC is somewhat dependend on debt financing.

		Industry Rank	Sector Rank
Debt/Equity	0.97
Debt/FCF	N/A
Altman-Z	3.6

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

HRC has a Current Ratio of 1.38. This is a normal value and indicates that HRC is financially healthy and should not expect problems in meeting its short term obligations.

A Quick Ratio of 1.05 indicates that HRC should not have too much problems paying its short term obligations.

		Industry Rank	Sector Rank
Current Ratio	1.38
Quick Ratio	1.05

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

HRC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.10%, which is quite good.

Measured over the past years, HRC shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.30% on average per year.

The Revenue has been growing slightly by 4.78% in the past year.

Measured over the past years, HRC shows a small growth in Revenue. The Revenue has been growing by 2.60% on average per year.

EPS 1Y (TTM)14.1%

EPS 3Y9.93%

EPS 5Y13.3%

EPS Q2Q%42.74%

Revenue 1Y (TTM)4.78%

Revenue growth 3Y1.96%

Revenue growth 5Y2.6%

Sales Q2Q%13.13%

3.2 Future

The Earnings Per Share is expected to grow by 10.11% on average over the next years. This is quite good.

Based on estimates for the next years, HRC will show a small growth in Revenue. The Revenue will grow by 5.87% on average per year.

EPS Next Y3.85%

EPS Next 2Y7.49%

EPS Next 3Y9.22%

EPS Next 5Y10.11%

Revenue Next Year3.75%

Revenue Next 2Y4.37%

Revenue Next 3Y5.68%

Revenue Next 5Y5.87%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 24.72, HRC is valued on the expensive side.

HRC's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.61.

Based on the Price/Forward Earnings ratio of 23.80, the valuation of HRC can be described as rather expensive.

The average S&P500 Price/Forward Earnings ratio is at 24.01. HRC is around the same levels.

		Industry Rank	Sector Rank
PE	24.72
Fwd PE	23.8

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	17.16

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates HRC does not grow enough to justify the current Price/Earnings ratio.

PEG (NY)6.41

PEG (5Y)1.86

EPS Next 2Y7.49%

EPS Next 3Y9.22%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

With a yearly dividend of 0.62%, HRC is not a good candidate for dividend investing.

With a Dividend Yield of 0.62, HRC pays less dividend than the S&P500 average, which is at 1.87.

		Industry Rank	Sector Rank
Dividend Yield	0.62%

5.2 History

The dividend of HRC is nicely growing with an annual growth rate of 6.42%!

HRC has paid a dividend for at least 10 years, which is a reliable track record.

Dividend Growth(5Y)6.42%

Div Incr YearsN/A

Div Non Decr YearsN/A

5.3 Sustainability

24.95% of the earnings are spent on dividend by HRC. This is a low number and sustainable payout ratio.

HRC's earnings are growing more than its dividend. This makes the dividend growth sustainable.

DP24.95%

EPS Next 2Y7.49%

EPS Next 3Y9.22%

More info and screens

Find the best dividend stocks

Show peers with best dividend

Hill Rom Holdings

NYSE:HRC (12/10/2021, 8:15:43 PM)

After market: 155.96 0 (0%)

155.96

+0.05 (+0.03%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)N/A N/A

Earnings (Next)02-15 2022-02-15/bmo

Inst Owners0%

Inst Owner Change0%

Ins Owners0.66%

Ins Owner Change0%

Market Cap10.42B

Revenue(TTM)3.02B

Net Income(TTM)248.50M

Analysts51.43

Price Target159.12 (2.03%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0.62%

Yearly Dividend0.94

Dividend Growth(5Y)6.42%

DP24.95%

Div Incr YearsN/A

Div Non Decr YearsN/A

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	24.72
Fwd PE	23.8
P/S	3.45
P/FCF	N/A
P/OCF	N/A
P/B	5.54
P/tB	N/A
EV/EBITDA	17.16

EPS(TTM)6.31

EY4.05%

EPS(NY)6.55

Fwd EY4.2%

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS45.2

BVpS28.15

TBVpSN/A

PEG (NY)6.41

PEG (5Y)1.86

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	4.97%
ROE	13.22%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	17.4%
PM (TTM)	8.23%
GM	N/A
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3Y0%

ROICexgc growth 5Y0%

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.6

Health

		Industry Rank	Sector Rank
Debt/Equity	0.97
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.38
Quick Ratio	1.05
Altman-Z	3.6

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)14.1%

EPS 3Y9.93%

EPS 5Y13.3%

EPS Q2Q%42.74%

EPS Next Y3.85%

EPS Next 2Y7.49%

EPS Next 3Y9.22%

EPS Next 5Y10.11%

Revenue 1Y (TTM)4.78%

Revenue growth 3Y1.96%

Revenue growth 5Y2.6%

Sales Q2Q%13.13%

Revenue Next Year3.75%

Revenue Next 2Y4.37%

Revenue Next 3Y5.68%

Revenue Next 5Y5.87%

EBIT growth 1YN/A

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1YN/A

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1YN/A

OCF growth 3YN/A

OCF growth 5YN/A

Hill Rom Holdings / HRC FAQ

What is the ChartMill fundamental rating of Hill Rom Holdings (HRC) stock?

ChartMill assigns a fundamental rating of 5 / 10 to HRC.

What is the valuation status for HRC stock?

ChartMill assigns a valuation rating of 3 / 10 to Hill Rom Holdings (HRC). This can be considered as Overvalued.

Can you provide the profitability details for Hill Rom Holdings?

Hill Rom Holdings (HRC) has a profitability rating of 6 / 10.

Can you provide the PE and PB ratios for HRC stock?

The Price/Earnings (PE) ratio for Hill Rom Holdings (HRC) is 24.72 and the Price/Book (PB) ratio is 5.54.

Can you provide the financial health for HRC stock?

The financial health rating of Hill Rom Holdings (HRC) is 4 / 10.

Hill Rom Holdings (HRC) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens

Hill Rom Holdings / HRC FAQ

What is the ChartMill fundamental rating of Hill Rom Holdings (HRC) stock?

What is the valuation status for HRC stock?

Can you provide the profitability details for Hill Rom Holdings?

Can you provide the PE and PB ratios for HRC stock?

Can you provide the financial health for HRC stock?